-+ 0.00%
-+ 0.00%
-+ 0.00%

Press Release: Seres Therapeutics Reports Third Quarter 2026 Financial Results and Announces Plans for Advancing Development of SER-155 To Prevent Immune Checkpoint Inhibitor-Related Enterocolitis (irEC)

Dow Jones·11/04/2026 12:03:08